BioPancrea is developing a research-stage, implantable artificial-pancreas concept combining beta-like cells, hydrogel and a vascular stent.

Did you know the American Diabetes Association’s 2026 Standards of…

The article explores the dual-edged nature of diabetes management technology, such as insulin pumps and continuous glucose monitors (CGMs), which have revolutionised care for type 1 diabetes patients but also pose significant risks. Tye Cummins nearly died after an Omnipod insulin pump delivered excessive insulin during sleep, highlighting the potential dangers of these devices. While evidence shows CGMs and pumps improve blood-sugar control and reduce complications, adverse event reports have surged, with diabetes devices ranking among the top 10 in TGA records. Concerns include accuracy issues, alarm failures, and connectivity problems with smartphones. Regulatory bodies like the TGA and US FDA face criticism for not adequately warning users about risks like Bluetooth interference with alarms, as seen in a fatal car crash linked to a CGM failure. Manufacturers defend their products, citing clinical evidence, but users report inaccuracies and safety concerns. The article underscores the tension between technological advancement and the need for robust safety measures, with calls for stricter regulations and transparency.

What is your professional background? I completed my MD and internal medicine residency in Houston at the University of Texas-Houston and Baylor, respectively. I then moved to California for my endocr...

Aims/hypothesis There is an unmet need for automated insulin adjustments for multiple daily injections in type 1 diabetes under unsupervised use. We aimed to assess the McGill decision support system ...

We're in 2026, and while our gadgets are practically reading our minds, how we find out about diabetes feels stuck in the Stone Age. It's time for an upgrade.